59 filings
Page 2 of 3
8-K
6j016 18j3cq
13 Mar 23
HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors
4:22pm
8-K
r1n5tqccy
20 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
lgkzf93gg0n bt3
15 Dec 22
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
4:09pm
8-K
tlf3gwqgs
14 Nov 22
Results of Operations and Financial Condition
7:14am
8-K
rn0r27f wk4sqaz
20 Oct 22
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
7:06am
8-K
mjk579ttiktu2igc
11 Aug 22
Results of Operations and Financial Condition
7:09am
8-K
5p7rf0z060cs2x
1 Jul 22
Amendments to Articles of Incorporation or Bylaws
8:06am
8-K
07t62qr ycl1
21 Jun 22
HOOKIPA Announces Executive Leadership Changes
5:47pm
8-K
fw21jhq4jdp7
6 Jun 22
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
7:00am
8-K
jqlo6c0pwma5g3h9aa
16 May 22
Results of Operations and Financial Condition
7:13am
8-K
zsc7zhw6y nf
2 May 22
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
5:31pm
8-K
6eore0p2koljlfwn5
20 Apr 22
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
4:18pm
8-K
0c7dse12
24 Mar 22
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
7:15am
8-K
0pal7oxbl n55l7lefb
3 Mar 22
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
5:21pm
8-K/A
fjb6u65s
1 Mar 22
Entry into a Material Definitive Agreement
4:12pm
8-K
4i6qg1y
1 Mar 22
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
4:09pm
8-K
uolyv
15 Feb 22
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
4:18pm
8-K
lay97gc5
1 Feb 22
Departure of Directors or Certain Officers
5:30pm
8-K
kjqe6esdd59k 4vm9
10 Nov 21
HOOKIPA Pharma Reports Third Quarter 2021 Financial Results and Recent Highlights
6:46am
8-K
1azl8e0fv4s75
9 Nov 21
HOOKIPA advances HB-200 program to Phase 2 and prioritizes oncology portfolio based on clinical data updates across its novel arenaviral platform
4:04pm